NEW YORK, April 23, 2021 /CNW/ — MindMed (Nasdaq:MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today that the Company’s subordinate voting shares have been approved for listing on The Nasdaq Capital Market (“Nasdaq”). Trading is expected to begin on Tuesday, April 27, 2021, under the symbol “MNMD” on the Nasdaq. MindMed will retain its listing on the Neo…


Previous articleChampignon Brands Announces Revocation of Cease Trade Orders
Next articlePTSF56 – Data vs. Spin, with Tim Cools of Psychedelic Experience